The study concluded that XO inhibition by febuxostat effectively ameliorates DKD by reducing oxidative stress and inflammation, primarily through a VEGFR1/3-dependent NOX-FoxO3a-eNOS signaling mechanism [70]. This evidence concerns the gene FLT1 and diabetic kidney disease.